Theravance Biopharma (TBPH) Stock Analysis & Winston Score

Theravance Biopharma is a biopharmaceutical company that discovers and develops medicines for serious lung diseases and other conditions. Its main product is YUPELRI (revefenacin), an inhaled treatment for chronic obstructive pulmonary disease (COPD) that is sold in the United States. The company focuses on patients with respiratory illnesses and works with healthcare providers and hospitals as its primary customers. Theravance earns revenue mainly through sales of YUPELRI, which it commercializes in partnership with Mylan (now part of Viatris), sharing costs and profits under a collaboration agreement. The company operates primarily in the United States and has a market cap of roughly $0.9 billion, reflecting its small size relative to larger biopharma peers. Its high gross margin shows the typical economics of a specialty drug business, but its near-zero operating margin means it is barely breaking even, and its main risk is heavy dependence on a single product in a competitive respiratory drug market.